H

ello, everyone, and how are you today? We are doing just fine, thank you, now that the biopharma Woodstock is winding down and our series of daily back-to-back meetings will soon come to end. This calls for a celebratory cup of stimulation, which yields a bit of an adventure in the City by the Bay, since the choices are endless. Such problems, yes? Meanwhile, here are some items of interest. Hope you have a smashing day and do stay in touch …

Endo Pharmaceuticals (ENDO) received a grand jury subpoena from the feds seeking documents relating to drugs containing oxymorphone. The subpoena seeks records produced in past or pending lawsuits and others relating to safety and efficacy; overdoses; diversion; theft; overprescribing; abuse; misuse; dependency; withdrawal; addiction, and adverse events. The feds also want distribution and third-party agreements; sales and marketing, training, financial, compensation and corporate information; and documents relating to interactions with government agencies.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy